生物制药企业Alto Neuroscience宣布,计划将近期融资所得款项专项投入其核心管线药物Alto-207的临床开发。该药物主要针对现有疗法效果不佳的难治性抑郁症患者群体,目前正处于关键研究阶段。公司表示,此项资金部署将加速推进Alto-207的临床试验进程,有望为全球数百万耐药性抑郁症患者提供新的治疗选择。
生物制药企业Alto Neuroscience宣布,计划将近期融资所得款项专项投入其核心管线药物Alto-207的临床开发。该药物主要针对现有疗法效果不佳的难治性抑郁症患者群体,目前正处于关键研究阶段。公司表示,此项资金部署将加速推进Alto-207的临床试验进程,有望为全球数百万耐药性抑郁症患者提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.